抗结核药物靶点的研究进展

Advances in targets of antituberculosis drugs

由结核分枝杆菌(Mycobacterium tuberculosis,Mtb)感染引起的结核病(TB)是世界上最致命的感染性疾病之一。因抗结核药物的泛用与滥用,细菌耐药问题日渐凸显。近几十年仅有2种抗结核新药上市,由于药物使用中的副作用及其耐药菌株的出现,急需开展针对Mtb新靶点的药物研究。本文围绕近几年全球最新报道的抗结核药物靶点及其相关化合物进行综述并加以系统总结,以期在一定程度上为新型抗结核药物的研发提供参考。

Tuberculosis(TB)is one of the world's most deadly infectious diseases caused by Mycobacterium tuberculosis(Mtb).Due to the widespread use and abuse of anti-tuberculosis drugs,the problem of bacterial drug resistance is becoming increasingly prominent.In recent decades,there are only two new anti-tuberculosis drugs in the market,due to the side effects of drug use and the emergence of drug-resistant strains,there is an urgent need to develop new drug targets for Mtb.In this paper,the targets and related compounds of anti-tuberculosis drugs reported in recent years are reviewed and systematically summarized in order to provide a reference for the research and development of new anti-tuberculosis drugs to some extent.